



Suggested Formula	Dimercaprol 100 mg/mL Intramuscular Injection (Solution, 10 mL)	FIN	F 008 909
-------------------	---	-----	-----------

### SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Dimercaprol, USP	1.000	g				
Benzyl Benzoate, NF	2.0	mL				
Peanut Oil, NF	q.s. to 10.0	mL				

### SPECIAL PREPARATORY CONSIDERATIONS


#### Ingredient-Specific Information

**Light Sensitive** (protect from light whenever possible):

*Dimercaprol, Benzyl Benzoate, Peanut Oil*

**Heat Sensitive** (protect from heat whenever possible):

*Benzyl Benzoate, Peanut Oil*





Suggested Formula	Dimercaprol 100 mg/mL Intramuscular Injection (Solution, 10 mL)	FIN	F 008 909
-------------------	---	-----	-----------

### SPECIAL PREPARATORY CONSIDERATIONS (CONTINUED)

#### Suggested Preparatory Guidelines

Non-Sterile Preparation     Sterile Preparation

Processing Error / Testing Considerations: To account for processing error, sterility and endotoxin testing considerations during preparation, it is suggested to measure an additional **30 to 40%** of the required quantities of ingredients.

Special Instruction: This formula may contain one or more Active Pharmaceutical Ingredients (APIs) that may be classified as hazardous, please refer & verify the current NIOSH list of Antineoplastic and Other Hazardous Drugs in Healthcare Settings. At this time, **General Chapter <800> Hazardous Drugs – Handling in Healthcare Settings** is informational and not compendially applicable unless otherwise specified by regulators and enforcement bodies. For information on the scope, intended applicability, and implementation context for USP General Chapter <800>, see: <https://www.usp.org/compounding/general-chapter-hazardous-drugs-handling-healthcare>.

This formula must be prepared within the appropriate facilities under adequate environmental conditions, following the necessary guidelines and procedures as stated within *USP 797* and *USP 800* when handling hazardous drugs. Only trained and qualified personnel must prepare this formula.

All heat stable, reusable materials and equipment must be sterilized and depyrogenated by dry heat sterilization at 250°C for 2 hours prior to use.

Compounder needs to verify as per USP, if every batch of final product compounded using this procedure must be sterility and endotoxin tested before being dispensed.

All required personal protective equipment (sterile and hazardous if applicable), such as but not limited to, gowns, aprons, sleeves, gloves both inner and outer if applicable, shoe covers, hairnet, head cap, beard cover, eyewear, appropriate face mask, respirator and face shield, etc., where applicable must be worn at all times. In addition, proper personnel cleansing must be done before entering the buffer or clean area.

If applicable, follow all required procedures for hazardous drug handling including but not limited to procurement, transport, storage, preparation, dispensing, administration, clean up (spills) & disposal.

Filter integrity must be validated by performing a filter stress test. If the test demonstrates that the filter might be defective, the solution must be discarded and remade.

If you are a registered 503B facility, please refer to all relevant guidance documents including but not limited to the Code of Federal Regulations (CFR), Guidance for Industry (GFI) and Compliance Policy Guides (CPGs).

This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.



Suggested Formula	Dimercaprol 100 mg/mL Intramuscular Injection (Solution, 10 mL)	FIN	F 008 909
-------------------	---	-----	-----------

**SUGGESTED PREPARATION (for 10 mL)**

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor (*): _____	Processing Error	Qty. to measure
Dimercaprol, USP §	1.000	g			
Benzyl Benzoate, NF §	2.0	mL			
Peanut Oil, NF §	q.s. to 10.0	mL			

\* Takes into account increased batch size conversions and density conversions, if required.

§ Weigh / measure just prior to use.

Preparatory Instruction

**IMPORTANT: All preparatory procedures must be performed using proper Aseptic Technique**

1.	<p><b><u>Equipment sterilization:</u></b></p> <p>Following the manufacturer's specifications, sterilize and depyrogenate all heat stable, reusable materials and equipment, then return to ambient temperature.</p>
2.	<p><b><u>Powder preparation:</u></b></p> <p>A. Combine and mix the following ingredients together:</p> <ul style="list-style-type: none"> <li>-Benzyl benzoate</li> <li>-Dimercaprol</li> </ul> <p><u>Specifications:</u> Continuously mix until homogenous.</p> <p><u>End result:</u> Homogeneous liquid-like solution.</p>
3.	<p><b><u>Filling to volume:</u></b></p> <p>A. Add Peanut Oil to the mixture (Step 2A) to fill to the required batch size (10.0 mL <i>plus</i> processing error adjustments).</p> <p><u>Specifications:</u> Continuously mix until homogenous.</p> <p><u>End result:</u> Homogeneous liquid-like solution.</p>
4.	<p><b><u>Filtering and transferring:</u></b></p> <p>Aseptically filter the solution through a 0.22-µm sterile Teflon filter into the recommended dispensing container (see Packaging requirements). Transfer the remainder into a separate dispensing container. This is to be used as the Test sample for sterility and endotoxin testing.</p>



Suggested Formula	Dimercaprol 100 mg/mL Intramuscular Injection (Solution, 10 mL)	FIN	F 008 909
-------------------	---	-----	-----------

5.	<p><b><u>Terminal Sterilization:</u></b></p> <p>In relation to the chemical composition of the formulation, final packaging, etc., select and validate an end-stage sterilization method and follow the manufacturer's specifications.</p>
6.	<p><b><u>Sterility and Endotoxin testing:</u></b></p> <p>Validate the Test sample for sterility and endotoxins, in accordance to current USP 797 regulatory guidelines.</p>

**SUGGESTED PRESENTATION**

Estimated Beyond-Use Date	24 hours controlled room temperature, 3 days refrigerated, or 45 days frozen, as per USP 797. BUD based on successful endotoxin test result.	Packaging Requirements	Sterile, light-resistant unit-dose serum vials sealed with serum bottle stopper .
Auxiliary Labels	1 Use as directed. Do not exceed prescribed dose.	6	Protect from light.
	2 Keep out of reach of children.	7	Discard container after use.
	3 Storage at low temperatures may result in the separation of some solid material which dissolves readily on warming.	8	Keep at controlled room temperature, (20°C – 25°C), refrigerated (2°C – 8°C) or frozen (-25°C to -10°C).
	4 Consult your health care practitioner if any prescription or over-the-counter medications are currently being used or are prescribed for future use.	9	Discard in the presence of particulate matter.
	5 Do not use if product changes color.	10	<b>For deep intramuscular use only.</b>
Pharmacist Instructions	Add any auxiliary labels specific to the API to the dispensing container as deemed necessary.		
Patient Instructions	Contact your pharmacist in the event of adverse reactions.		



Suggested Formula	Dimercaprol 100 mg/mL Intramuscular Injection (Solution, 10 mL)	FIN	F 008 909
-------------------	---	-----	-----------

## REFERENCES

1.	Parenteral Preparations. In: Allen, LV, Jr. <i>The Art, Science, and Technology of Pharmaceutical Compounding Fifth Edition</i> . American Pharmacists Association; 2016: 399.
2.	Benzyl Benzoate. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients, 8<sup>th</sup> Edition</i> . American Pharmaceutical Association; 2017: 108.
3.	Dimercaprol. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference, 38<sup>th</sup> Edition</i> . London, England: The Pharmaceutical Press; 2014: 1549.
4.	Dimercaprol (Monograph). <i>United States Pharmacopeia XLIII / National Formulary 38</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2020: 1411.
5.	USP <797>. <i>United States Pharmacopeia XLIII / National Formulary 38</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2020: 7037.

DISCLAIMER: THIS DOCUMENT IS COPYRIGHT© 2020 MEDISCA PHARMACEUTIQUE INC. MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY, SCHEDULING OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW. MEDISCA NETWORK INC. MAKES NO WARRANTIES WITH RESPECT TO INFRINGEMENT OR NON-INFRINGEMENT BY THE FORMULA OF ANY PATENT OR OTHER INTELLECTUAL PROPERTY OF ANY OTHER PARTY, AND IT IS THE RESPONSIBILITY OF THE PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL TO INVESTIGATE AND DETERMINE ANY SUCH ISSUE.